<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7027">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03015441</url>
  </required_header>
  <id_info>
    <org_study_id>NU378</org_study_id>
    <nct_id>NCT03015441</nct_id>
  </id_info>
  <brief_title>Evaluation of a 28-day Fermented Milk Product Consumption Twice Daily as Compared to a Non-fermented Milk Product on Intestinal Gas Production in Healthy Subjects High Dihydrogen Producers</brief_title>
  <acronym>BREEZE</acronym>
  <official_title>Evaluation of a 28-day Fermented Milk Product Consumption Twice Daily as Compared to a Non-fermented Milk Product on Intestinal Gas Production in Healthy Subjects High Dihydrogen Producers A Randomized, Controlled, Double-blind, Parallel Arms, Adaptive Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danone Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danone Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of a 28-day fermented milk product
      consumption twice daily on intestinal gas production of dihydrogen (H2) and methane (CH4) in
      healthy subjects high H2 producers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2, 2017</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison between groups of the change from baseline (Day0) of breath H2 production elicited by a lactulose challenge test after 28 days of investigational product consumption</measure>
    <time_frame>Baseline and after 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison between groups of the change from baseline (Day0) of breath H2 production elicited by a lactulose challenge test after 14 days of investigational product consumption</measure>
    <time_frame>Baseline and after 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between groups of the change from baseline (Day0) of breath CH4 production elicited by a lactulose challenge test after 14 days and 28 days of investigational product consumption</measure>
    <time_frame>Baseline, after 14 days and after 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between groups of the change from baseline (Day0) in the fasting breath H2 and CH4 values after 14 days and 28 days of investigational product consumption</measure>
    <time_frame>Baseline, after 14 days and after 28 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Comparison between groups of the change in composition and activity of gut microbiota from stool samples collected before and after 28 days of investigational product consumption</measure>
    <time_frame>Baseline, after 28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adverse event</measure>
    <time_frame>AE and SAE assessment through study completion and up to 14 days after the last study visit</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Excessive Intestinal Gas Production</condition>
  <arm_group>
    <arm_group_label>Arm 1: Fermented milk product containing probiotics</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Milk-based non-fermented dairy product</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Milk product fermented by lactic bacteria or not fermented</intervention_name>
    <description>2 pots of 125g consumed daily during 28 days</description>
    <arm_group_label>Arm 1: Fermented milk product containing probiotics</arm_group_label>
    <arm_group_label>Arm 2: Milk-based non-fermented dairy product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject with body mass index (BMI) between 18.0 and 30.0 kg/m2 (bounds excluded)

          -  Subjects having a high dihydrogen (H2) production as defined by a fasting exhaled
             level of H2 in breath at 10 parts per million (ppm) or more.

          -  Women of childbearing potential must be using a medically approved method of
             contraception OR women must be postmenopausal for at least 12 months prior to study
             entry

        Exclusion Criteria:

          -  Subject with functional gastrointestinal disorder according to ROME III criteria
             (Functional Bowel Disorders/FBD module, Functional Dyspepsia/FD module, Irritable
             Bowel Syndrome/IBS module)

          -  Subject with gastrointestinal disorders according to investigator's medical
             assessment

          -  Subject taking drugs that might modify gastrointestinal function

          -  Subject with severe disease as assessed by the investigator (ex: cancer, severe heart
             disease, kidney disease, neurological disease or psychiatric disease,
             immunodeficiency disorder)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boris Le NEVE, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Danone Research, Palaiseau, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-François JEANNE</last_name>
    <phone>+33 (0) 1 69 35 68 72</phone>
    <email>Jean-francois.jeanne@danone.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CRS Clinical Research Services Mannheim GmbH</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friedeborg SEITZ, MD</last_name>
      <phone>+49 621 15045 152</phone>
      <email>Friedeborg.Seitz@crs-group.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 8, 2017</lastchanged_date>
  <firstreceived_date>January 2, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy subjects</keyword>
  <keyword>Probiotics</keyword>
  <keyword>Breath test</keyword>
  <keyword>Dihydrogen</keyword>
  <keyword>Methane</keyword>
  <keyword>Intestinal gas production</keyword>
  <keyword>Gut microbiota</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
